Severe diarrhoea during Campath-1H treatment for refractory cutaneous T-cell lymphoma [1]

Annals of Hematology

Volumn 85, Issue 9, 2006, Pages 617-619

  Goteri, Gaia ^a   Rupoli, Serena ^a   Tassetti, Angela ^a   Pulini, Stefano ^a   Morichetti, Doriana ^a   Filosa, Alessandra ^a   Mandolesi, Alessandra ^a   Veccia, Salvatore ^a   Leoni, Pietro ^a   Bearzi, Italo ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; COTRIMOXAZOLE; FLUCONAZOLE; PIPERACILLIN PLUS TAZOBACTAM; VALACICLOVIR;

AGED; CASE REPORT; CHEMOPROPHYLAXIS; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; ENDOSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; INTESTINE BIOPSY; KIDNEY DYSFUNCTION; LETTER; MALE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL;

AGED; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; COLON; DIARRHEA; ESCHERICHIA COLI INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOMA, T-CELL, CUTANEOUS; MALE; TIME FACTORS;

EID: 33747837493     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-006-0116-2     Document Type: Letter

References (12)

1. Dearden CE, Matutes E, Catovsky D (2002) Alemtuzumab in T-cell malignancies. Med Oncol 19:S27
2. Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, Schetelig J, Seipelt G, Osterborg A (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103:2920
3. Gibbs DS, Westerman D, McCormack C, Seymour JF, Prince HM (2005) Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Br J Haematol 130:87
4. Keating M, Coutre S, Rai K, Osterborg A, Faderl S, Kennedy B, Kipps T, Bodey G, Byrd JC, Rosen S, Dearden C, Dyer MJ, Hillmen P (2004) Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukaemia. Clin Lymphoma 4:220
5. Kennedy GA, Seymour JF, Wolf M, Januszewicz H, Davison J, McCormack C, Ryan G, Prince HM (2003) Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol 71:250
6. Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, Rosenblad E, Tjonnfjord G, Wiklund T, Osterborg A (2003) Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101:4267
7. Lundin J, Porwitt-MacDonald A, Rossmann ED, Karlsson C, Edman P, Rezvany MR, Kimby E, Osterborg A, Mellstedt H (2004) Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 18:484
8. Orenstein JM, Kotler DP (1995) Diarrheogenic bacterial enteritis in acquired immune deficiency syndrome: A light and electron microscopy study of 52 cases. Human Pathol 26:481
9. Rai K, Hallek M (2002) Future prospects for alemtuzumab (MabCampath). Med Oncol 19:S57
10. Salisbury JR, Rapson NT, Codd JD, Rogers MV, Nethersell AB (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin lymphomas. J Clin Pathol 47:313
11. Thursky KA, Worth LJ, Seymour JF, Prince HM; Slavin MA (2005) Spectrum of infections, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 132:3
12. Tang SC, Hewitt K, Reis MD, Berinstein NL (1996) Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leuk Lymphoma 24:93